GV, Alphabet Inc's venture capital arm, led a $58.5 million investment to launch Verve Therapeutics, a new biotech focused on developing therapies that edit the human genome to treat heart diseases.
from Reuters: Health https://reut.rs/2H8B9Hf
via
IFTTT
0 comments: